Allogene Reports Q2 2026 Financials and Clinical Trial Updates
In the second quarter of 2026, Allogene (ALLO) reported a net loss of $42.7 million or $0.13 per share, driven by research and development expenses as well as general administrative costs. The company generated collaboration revenue of $4.6 million from related party agreements during the quarter. Allogene highlighted progress in its clinical trials, particularly with cema-cel showing 58.3% minimal residual disease negativity compared to 16.7% in a control group. Additionally, Allo-316 demonstrated an overall response rate of 31% for patients with CD70 high renal cell carcinoma using the optimized regimen. The company also noted that it has $423.6 million in cash and investments, projecting sufficient funds to last through 2029. Management emphasized its focus on developing allogeneic CAR T therapies designed for outpatient use.
Topics: clinical trial data financial results research progress